Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units (the “Unit”) of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”). The gross proceeds to the Company from the Offering are expected to be approximately US$20 million, before deducting underwriting discounts and commission and other expenses. Each Unit will be comprised of one common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one common share at a price of US$1.85 per common share, subject to adjustment in certain events, during a period of 60 months following the date of the closing of the Offering.
